Patent US4851233A successfully refreshed from Google Patents.
US4851233A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release formulations
Assignee: Warner Lambert Co LLC
•
Filing: 1986-10-06
•
Granted: 1989-07-25
•
Expires: 2006-10-06
Abstract
Abstract A new drug delivery system, which gives sustained release properties is made by combining certain cellulosic polymers with cellulose in a binder system.
Inventors
- 👤 Sadath U. Khan
- 👤 Reginald Phillips
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 12:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61K31/21; A61K31/215; A61K31/235; A61K31/24; A61K31/245; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
92 words
A compressed tablet binder system mixture consisting essentially of: (a) about 60-90 wt % of procainamide hydrochloride or sodium meclofenamate, (b) about 5-20 wt % of a Type "H" hydroxy ethyl cellulose, and (c) about 5-15 wt % of microcrystalline cellulose, which is further coated by the hydroxy ethyl cellulose; said hydroxy ethyl cellulose rapidly hydrating to a transient gel state which persists long enough to provide a sustained dissolution with drug release occurring via a slow diffusion and matrix erosion; said tablet being completely disintegrated at the end of drug dissolution.
Claim 2
Dependent Claim
92 words
A compressed tablet binder system mixture consisting essentially of: (a) about 60-90 wt % of procainamide hydrochloride or sodium meclofenamate, (b) about 5-20 wt % of a Type "H" hydroxy ethyl cellulose, and (c) about 5-15 wt % of microcrystalline cellulose, which is further coated by the hydroxy ethyl cellulose; said hydroxy ethyl cellulose rapidly hydrating to a transient gel state which persists long enough to provide a sustained dissolution with drug release occurring via a slow diffusion and matrix erosion; said tablet being completely disintegrated at the end of drug dissolution.
Claim 3
Dependent Claim
10 words
The composition of claim 1 wherein (a) comprises procainamide hydrochloride.
Claim 4
Dependent Claim
10 words
The composition of claim 1 wherein (a) comprises sodium meclofenamate.
References Cited (Backward Citations)
US4309404A
Cited
US4252786A
Cited
US4369172A
Cited
US4525345A
Cited
US4389393A
Cited
US4389393B1
Cited
US4461759A
Cited
US4505890A
Cited
US4555399A
Cited
US4610870A
Cited
US4792452A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-24 | 1993-01-23 | 1993-07-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-24 | 1997-01-23 | 1997-07-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-24 | 2001-01-23 | 2001-07-25 | $7700.00 | Window Closed / Lapsed |